Is the use of cetuximab in the first-line treatment of recurrent/metastatic head and neck cancer still important?

被引：0
|
作者：
Vitale, Pasquale [1 ]
De Falco, Vincenzo [1 ]
Addeo, Raffaele [1 ,2 ]
机构：
[1] Hosp Frattamaggiore, Oncol Operat Unit, Frattamaggiore, Italy
[2] ASLNA2NORD, San Giovanni Dio Hosp, Oncol Operat Unit, Via D Pirozzi 62, I-80027 Frattamaggiore, NA, Italy
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2024年 / 24卷 / 07期
关键词：
Recurrent/metastatic head and neck cancer; cetuximab; PD-L1; pembrolizumab; chemotherapy; combined positive score; SQUAMOUS-CELL CARCINOMA; CHEMOTHERAPY PLUS CETUXIMAB; RECURRENT; PEMBROLIZUMAB; KEYNOTE-048;
D O I：
10.1080/14737140.2024.2354772
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：481 / 484
页数：4
相关论文
共 50 条
  • [31] First-Line Nivolumab Plus Ipilimumab in Recurrent/Metastatic Head and Neck Cancer-What Happened?
    Burtness, Barbara
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (12) : 2134 - +
  • [32] First-line treatment in metastatic colorectal cancer: Important or crucial?
    Malka, David
    Rotolo, Federico
    Boige, Valerie
    EUROPEAN JOURNAL OF CANCER, 2017, 84 : 363 - 366
  • [33] Cetuximab since 10 Years in the First-line Standard for Patients with Head and Neck Cancer
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (06) : 407 - 407
  • [34] First line cetuximab and cisplatin with or without paclitaxel in recurrent/metastatic head and neck cancer: A randomized phase IIb trial
    Bossi, P.
    Hollander, L. H.
    Miceli, R.
    Ferrari, D.
    Vecchio, S.
    Moretti, G.
    Merlano, M.
    Caponigro, F.
    Moro, C.
    Vaccher, E.
    Alabisio, O.
    Caldara, A.
    Russo, A.
    Ferrau, F.
    Nole, F.
    Licitra, L.
    ANNALS OF ONCOLOGY, 2017, 28
  • [35] Monalizumab, cetuximab and durvalumab in first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): A phase II trial
    Colevas, D. A.
    Misiukiewicz, K.
    Pearson, A. T.
    Fayette, J.
    Bauman, J. R.
    Cupissol, D.
    Saada-Bouzid, E.
    Adkins, D. R.
    Marie, D. B.
    Cornen, S. L.
    Andre, P.
    Carrette, F.
    Rotolo, F.
    Boyer Chammard, A.
    Cohen, R. B.
    ANNALS OF ONCOLOGY, 2021, 32 : S1432 - S1432
  • [36] Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study
    Guigay, J.
    Fayette, J.
    Dillies, A. F.
    Sire, C.
    Kerger, J. N.
    Tennevet, I.
    Machiels, J. P.
    Zanetta, S.
    Pointreau, Y.
    Bozec Le Moal, L.
    Henry, S.
    Schilf, A.
    Bourhis, J.
    ANNALS OF ONCOLOGY, 2015, 26 (09) : 1941 - 1947
  • [37] Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy
    Siano, Marco
    Infante, Gabriele
    Resteghini, Carlo
    Cau, Maria Chiara
    Alfieri, Salvatore
    Bergamini, Cristiana
    Granata, Roberta
    Miceli, Rosalba
    Locati, Laura
    Licitra, Lisa
    Bossi, Paolo
    ORAL ONCOLOGY, 2017, 69 : 33 - 37
  • [38] Persistent Head and Neck Cancer Following First-Line Treatment
    Steinbichler, Teresa Bernadette
    Lichtenecker, Madeleine
    Anegg, Maria
    Dejaco, Daniel
    Kofler, Barbara
    Schartinger, Volker Hans
    Kasseroler, Maria-Therese
    Forthuber, Britta
    Posch, Andrea
    Riechelmann, Herbert
    CANCERS, 2018, 10 (11):
  • [39] Pembrolizumab in the first-line treatment of advanced head and neck cancer
    de Sousa, Luana Guimaraes
    Ferrarotto, Renata
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (12) : 1321 - 1331
  • [40] A phase 2 study of ipatasertib in combination with pembrolizumab for first-line treatment of recurrent or metastatic squamous cell cancer of the head and neck
    Thomas, Jacob Stephen
    Bruce, Justine Yang
    Li, Zujun
    Lorch, Jochen H.
    Phillips, Tanyanika
    Villaflor, Victoria
    Ruel, Christopher
    Palmer, Joycelynne
    Gutkind, J. Silvio
    Villalona-Calero, Miguel Angel
    Colevas, Alexander Dimitrios
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345